Optimizing Antibody Variant Capture: Strategies To Combat Aggregation, Impurities, And Low Yields

The increased diversity of antibody derived molecules introduces substantial purification challenges. For instance, bispecific antibodies are more prone to aggregation, tend to exhibit higher levels of product-related impurities, and often have low titers compared to conventional monoclonal antibodies (mAbs). Addressing these issues is crucial for ensuring a robust, safe, and economically viable production process.

In this video, we will discuss how process conditions influence stability of the target antibody and can introduce impurities (e.g., acid-induced aggregation) and strategies for efficiently removing product-related impurities during the purification of asymmetric bispecific antibodies (bsAbs).

Speakers: Mats Ander, Vlatko Stojanoski, and Mikael Gudmundsson.